Why HealthTech requires specialized diligence
Healthcare companies operate inside regulated workflows with fragmented buyers, complex reimbursement, long procurement cycles, and high switching costs. A product can produce compelling clinical results and still fail if it does not fit the way care is delivered or purchased.
The five questions seed investors should answer
1. Does the product solve a costly, frequent problem?
The strongest opportunities address pain that is measurable in clinical outcomes, labor, revenue-cycle performance, capacity, or risk.
2. Who uses it, who benefits, and who pays?
These may be three different stakeholders. Strong underwriting identifies each party and tests whether incentives reinforce or obstruct adoption.
3. Can it enter the existing workflow?
Adoption improves when technology removes steps, documentation burden, delay, or uncertainty. Products requiring substantial behavior change need unusually strong benefits.
4. Is the regulatory and evidence pathway financeable?
Investors should map FDA classification, clinical evidence, privacy requirements, reimbursement dependencies, and expected capital needs to specific milestones.
5. Can the company reach buyers efficiently?
Commercial plans should specify the decision-maker, budget owner, sales cycle, implementation burden, and proof required for expansion.
M3A's perspective
M3A combines these questions with operator and physician pattern recognition. The objective is to identify companies where specialized support can improve the probability and speed of clinical and commercial adoption.